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Abstract: The increasing frequency of monkeypox virus infections, new outbreaks of other zoonotic
orthopoxviruses and concern about the re-emergence of smallpox have prompted research into
developing antiviral drugs and better vaccines against these viruses. This article considers the
genetic engineering of vaccinia virus (VACV) to enhance vaccine immunogenicity and safety.
The virulence, immunogenicity and protective efficacy of VACV strains engineered to lack specific
immunomodulatory or host range proteins are described. The ultimate goal is to develop safer and
more immunogenic VACV vaccines that induce long-lasting immunological memory.
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1. Introduction
The development of vaccines and subsequent widespread vaccination has resulted in the
eradication of two virus diseases, smallpox [1] and rinderpest [2], the control of several others and,
together with other factors such as improved hygiene, has led to improved animal welfare and an
increase in human life expectancy. Scientific research has provided vaccines against several other
diseases that could be eradicated (measles, mumps and rubella (MMR), for instance) but there has
been insufficient will to ensure adequate vaccine usage to achieve eradication. For example, despite
the live attenuated vaccine against measles having been available for more than 50 years and its use
having greatly decreased the incidence of measles and prevented an estimated 20 million deaths
between 2000 and 2015 [3,4], the disease remains and is resurgent due to under-utilisation of the
vaccine. This under-utilisation has been fuelled by the erroneous claim that MMR causes autism,
the increased activity of anti-vaccination groups, the decreased concern about the disease as it became
less common and political apathy. In consequence, there have been serious outbreaks of measles in
several countries including USA (Minnesota, 2017) [5], England and Wales (more than 2000 cases
in 2012 and the highest level for 2 decades) [6–8], other parts of Europe [9] and Latin America [10].
This highlights the importance of maintaining vaccination to prevent the dissemination of infectious
diseases. The eradication of measles and some other infectious diseases remains an achievable goal
and we should be inspired by the eradication of both rinderpest and smallpox.
Smallpox was a greatly feared infectious disease that caused hundreds of millions of deaths
since it was first reported approximately >3000 years ago [11]. Indeed, in the 20th century alone,
more than 100 years after an effective vaccine was available, smallpox killed an estimated 400 million
people. Smallpox was caused by Variola virus (VARV), a member of the Orthopoxvirus genus of the
Poxviridae [12]. Unlike several other orthopoxviruses, such as cowpox virus (CPXV) and monkeypox
virus (MPXV) that infect a wide range of mammals, VARV was restricted to a single species,
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Homo sapiens and this restriction contributed greatly to smallpox eradication. An ancient strategy
to prevent smallpox was “variolation” or “inoculation” that consisted of the deliberate infection of
people, usually in the arm, with infectious material taken from pustules from a prior case of smallpox.
This practice was introduced into Europe by Mary Wortley Montagu, who observed this practice
among the Turks in Constantinople in 1717. This procedure was dangerous and was associated with a
fatality rate of 0.5–2% (due to smallpox), yet it was used because of the much greater fatality rate of
natural smallpox (20–30%) [11,13]. Variolation prevented natural cases of smallpox, but it also enabled
VARV to spread from variolated people and contributed to smallpox outbreaks [11]. Nonetheless,
it was the only means to prevent smallpox until 1796 when Edward Jenner introduced vaccination.
Jenner and others had observed that milkmaids who were infected by CPXV acquired a local mild
disease and subsequently were resistant to smallpox [14]. Jenner was credited with the invention of
vaccination because he set out to test experimentally the hypothesis that it was the prior infection with
cowpox that prevented subsequent smallpox. Jenner first vaccinated a boy, James Phipps, with cowpox
material taken from the hand of a milkmaid, Sarah Nelmes, and a few weeks later challenged Phipps
with VARV (variolation). The child was resistant to variolation and, after repeating the experiment in
several other children, Jenner published his observation privately in 1798 [14]. Jenner was convinced
of the effectiveness of this practice and in 1801 he predicted the eradication of smallpox saying, “It now
becomes too manifest to admit of controversy that the annihilation of smallpox, the most dreadful
scourge of the human species, must be the final result of this practice” [15].
The process Jenner introduced became known as “vaccination” and the agent used as a “vaccine”
after the Latin word for cow, “vacca,” for reviews see [16,17]. The principle behind the efficacy
of vaccination against smallpox, unknown to Jenner, relies on the antigenic conservation and
cross-protective nature of orthopoxviruses, such that prior infection by one orthopoxvirus provides
protection against subsequent infection by any other orthopoxvirus [11,18]. During the 19th century,
Jenner’s vaccine against smallpox was spread around the world but it was not until 1959 that the
World Health Assembly adopted a resolution to achieve the global eradication of smallpox. In 1967
an intensified smallpox eradication campaign began that utilised surveillance, quarantine and ring
vaccination. This was highly effective and in just 10 years resulted in the global eradication of smallpox.
The last naturally occurring case was in Somalia in 1977 and after a further 2 years of surveillance
the WHO certified eradication was complete [1] thereby fulfilling Jenner’s prophecy. Several factors
contributed to the success of this programme. These included the fact that VARV infected only humans,
it did not establish latent or persistent infections, the disease was easily recognisable, the causative
agent was genetically stable and did not escape existing immunity by antigenic variation and the
vaccine was plentiful, cheap, stable and easy to administer. Most important there was widespread
enthusiasm and drive to see the job completed.
2. Continuing Threat of Smallpox and Other Zoonotic Orthopoxviruses
2.1. Remaining VARV Stocks
Despite eradication of the disease smallpox, the causative agent, VARV, remains in two high
security laboratories: one in the State Research Centre of Virology and Biotechnology (Vector) in the
Russian Federation and one at the Centers for Disease Control and Prevention (CDC) in the USA.
Following the eradication of smallpox, all known stocks of VARV were catalogued and centralised in
these maximum-security laboratories. Thereafter, the WHO asked the WHO Ad Hoc Committee on
Orthopoxviruses to consider what should happen to the remaining VARV stocks. After debate,
the Committee recommended in 1994 that all remaining stocks of VARV should be destroyed.
This recommendation was adopted by the World Health Assembly in 1996 and the destruction
scheduled for 1999. In the meantime, limited work with VARV in these two high security laboratories
was permitted to enable essential research for public health benefit. This work was limited to the
development of diagnostic tests for cases of smallpox, antiviral drugs that could treat smallpox and a
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safer vaccine that would be tolerated by those in whom use of the conventional smallpox vaccine was
contraindicated. To oversee this research the WHO set up the Advisory Committee on Variola Virus
Research (ACVVR). This committee has met annually since 1999 and reported on progress towards
the research objectives for 19 consecutive years and, although considerable progress has been made,
the work is considered incomplete and the VARV stocks have not been destroyed.
2.2. Recreation of Orthopoxviruses by Synthetic Biology
While temporary retention of VARV has been permitted, an additional complication has arisen,
namely methods to recreate an orthopoxvirus from chemicals using synthetic biology. Since 2001 it has
been possible to recover a live orthopoxvirus from non-infectious DNA by the introduction of this DNA
into cells that are then infected by a different poxvirus [19]. Recently, this was repeated with horsepox
virus (HSPV) but in this case the virus was recreated by the synthesis of virus genome fragments from
chemicals, rather than by using existing cloned DNA, followed by the introduction of these fragments
into cells [20]. These cells were then infected with another (helper) poxvirus and live HSPV was
recovered from these cells. The genome sequences of about 50 strains of VARV have been determined
and are in the public domain [21,22]. What is possible for one orthopoxvirus will be possible for others,
so there is little doubt that live VARV could be recreated from simple chemicals. This has never been
done, it would take a sustained and deliberate effort and is prohibited absolutely by the WHO. Also
prohibited is any genetic engineering with VARV, the holding of more than 20% of a VARV genome in
any laboratory outside the 2 high security laboratories permitted to hold VARV and the introduction
of any VARV DNA into any laboratory that holds any other live orthopoxvirus [23]. These restrictions
are designed to eliminate any possibility that VARV, or a virus with VARV-like properties, could be
recreated accidentally by recombination between VARV DNA and another orthopoxvirus genome
inside living cells.
The possible deliberate use of VARV in bioterrorism has been of heightened concern after the
9/11 terrorist attacks in USA, for if terrorists were willing to commit mass murder by flying aeroplanes
into densely populated buildings, would they hesitate to release VARV if they had access to it [24]?
Further, there are concerns about unofficial stocks of VARV that have been retained accidentally or
deliberately [25]. The discovery of vials containing infectious VARV at the National Institutes of Health
(NIH), Bethesda, USA in 2014 highlighted this issue [26]. There is also concern that infectious VARV
might be present within corpses of victims of smallpox that have been buried in permafrost. Although
no infectious VARV has been found in buried smallpox victims, fragmented pieces of VARV DNA are
present in such material and it has been possible by mass DNA sequencing and computer-mediated
DNA analysis to deduce a full VARV genome sequence from a mummified corpse of a VARV victim
who died in Vilnius, Lithuania, around 1650 [27].
Arguments for the destruction of VARV stocks have included: (i) destruction being the natural
conclusion of the smallpox eradication campaign; (ii) the removal of the risk of virus escape from
these laboratories; and (iii) the elimination of the costs associated with storing the virus safely and
securely [24]. The principal argument against the destruction of all VARV stocks now is the possibility
that live virus might be needed to evaluate new drugs against smallpox [28,29].
2.3. Emergence and Re-Emergence of Orthopoxviruses
As smallpox was eliminated country by country, smallpox vaccination declined and was stopped
after eradication was certified in 1979. Indeed, routine vaccination against smallpox was discontinued
in many countries prior to eradication. Consequently, very few people are vaccinated nowadays so
that a large proportion of the world’s population is unvaccinated and therefore potentially at risk from
VARV and other orthopoxviruses [30]. At present, infections of humans by zoonotic orthopoxviruses
are increasing. Of these, MPXV is of greatest concern and causes a severe, smallpox-like disease in
humans, with a mortality rate of 1–8% [31]. Although monkeypox has occurred mostly in central
Africa such as in the Democratic Republic of the Congo (DRC), cases have been reported in other
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African countries and, in 2003, a zoonotic outbreak occurred in the USA, caused by the importation of
MPXV-infected rodents from West Africa [32]. In 2017, there were outbreaks of monkeypox in several
African nations including Nigeria, DRC and Republique Centre Africaine (RCA) [33]. Furthermore,
cases of human monkeypox have increased in DRC over the last 30 years and one contributory factor
is the increasing proportion of the population that is immunologically naïve to orthopoxviruses
following cessation of smallpox vaccination [34]. Another factor that enhances the likelihood of
orthopoxvirus infections in humans is the human immunodeficiency virus (HIV) epidemic and
the consequential acquired immune deficiency syndrome (AIDS). Viruses that are prevented from
becoming established in humans by a fully functional immune system have increased opportunity
to infect and spread in those with an impaired immune system and thereafter to adapt and acquire
human-to-human transmission.
In Europe in the last two decades, there have been increased CPXV outbreaks, some resulting
from transmission from pet animals to humans [35–38]. Although infections are a sporadic cause of
disease in domestic animals [39,40] and humans [41], CPXV can also cause severe and sometimes fatal
disease in immunosuppressed individuals [42–44].
Lastly, zoonotic vaccinia virus (VACV) outbreaks have been described in Asia and South
America [30]. The clinical presentation of VACV infection in humans is usually associated with
localised exanthematous lesions but systemic clinical manifestations can also occur [45]. In India,
buffalopox (caused by a VACV strain) outbreaks have been reported since 1934, but outbreaks of
buffalopox have also been reported in Nepal, Pakistan, Indonesia and Egypt. Buffalopox affects mainly
buffaloes, though infection of humans has also been recorded [46,47]. In Brazil, VACV circulation
was first reported in the 1960s and 1970s, however the first outbreak involving cattle and humans
was only reported in 1999 [45,48]. Thereafter, several other outbreaks were reported, affecting mainly
bovines, equines, rodents and humans [49–52]. The extent of VACV circulation in Brazil is uncertain
because of misdiagnosis and underreporting [45]. Moreover, evidence of VACV circulation was also
found in Amazon monkeys and semi-domestic rodents, suggesting the virus is circulating in the
wild [53,54]. More recently, VACV circulation has also been detected in cattle from Argentina, Uruguay
and Colombia [55–57].
Emergence of novel orthopoxviruses also poses a threat to an increasingly immunologically
naïve population, as shown by the recent cases in humans in Georgia and in Alaska, USA [58,59].
Both reports highlight the zoonotic nature of these infections, as was an outbreak of an uncharacterised
orthopoxvirus in macaques in an Italian primate sanctuary [60].
3. Vaccine Development against Smallpox and Other Orthopoxviruses
Initially, smallpox vaccine material was obtained from lesions of cows presumably infected with
CPXV and live vaccine was retained by arm-to-arm vaccination in humans or by skin scarification in
animals, such as bovine calves [11]. In 1939, the smallpox vaccines being used in the 20th century were
shown to be distinct from CPXV and were termed VACV [61]. So, if Jenner used CPXV in 1796 (and
this is not certain given the virus is no longer available for analysis), sometime between 1796 and 1939
VACV had replaced CPXV as the smallpox vaccine. This is likely to have occurred in the 19th century
because late 19th century pathologists described the eosinophilic cytoplasmic inclusion bodies caused
by the smallpox vaccine (and that are made by both VACV and CPXV) but did not mention the more
obvious A type inclusion bodies that are made by CPXV but not VACV. Interestingly, sequence analysis
of a smallpox vaccine sample from USA in 1902 indicated that this is most closely related to HSPV [62].
The actual virus used by Jenner in 1796 has often been reviewed but remains uncertain [17,63,64].
VACV, HSPV, CPXV and VARV are all orthopoxviruses and are all antigenically related and
cross-protective due to the high degree of amino acid sequence conservation of their structural
proteins [18]. Many VACV strains were used during the WHO smallpox eradication campaign
and, prior to vaccination procedures and quality control methods being standardised, the vaccines
varied from country to country [11]. The VACV strains Lister, Copenhagen (Cop), chorioallantois
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vaccinia Ankara (CVA), Tian Tan (TT), Bern and New York City Board of Health (NYCBH) are
examples of strains used during the eradication programme, known as first-generation smallpox
vaccines [11,13,65]. It was recognised that these VACV strains induced different frequencies of
vaccine-related complications and consequentially strains such as Bern and Copenhagen were less
favoured in comparison to Lister and NYCBH [11,66]. After smallpox had been eradicated, vaccine
production switched to the use of embryonated chicken eggs or tissue culture cells to reduce bacterial
contamination and allergies to animal proteins [65]. Later some vaccine strains were plaque purified,
such as the ACAM-2000 strain derived from Dryvax/NYCBH [67] and are called second-generation
smallpox vaccines [13]. ACAM-2000 is currently the only smallpox vaccine licensed by the Food and
Drugs Administration (FDA) and available for use in the USA [68].
In addition to switching smallpox vaccine production to use modern good manufacturing
practice (GMP), safer vaccine strains were sought that did not cause the troublesome vaccine-related
complications. Repeated passage of the first-generation vaccines in either avian or mammalian
cultured cells enabled isolation of attenuated viruses, in the same way that many live attenuated
virus vaccines were produced, such as those for yellow fever, polio (Sabin), measles, mumps and
rubella. These third-generation smallpox vaccines include LC16m8 that was derived from strain
Lister by Hashizume and colleagues in Japan [69] and modified vaccinia virus Ankara (MVA) that
was derived from strain CVA by Mayr and colleagues in Germany [70]. MVA was obtained after
572 passages of the CVA strain in chicken embryo fibroblasts (CEFs) and this resulted in the loss
of nearly 15% of its genome, due to six large deletions and many smaller mutations [71,72]. MVA
is unable, or barely able, to replicate in most mammalian cells in culture, including human cells
and lacks several immunomodulators and host range genes expressed by other VACV stains [73,74].
MVA is immunogenic and avirulent in animal models, is considered safe for human use, including
in immunosuppressed people due to its incapacity to replicate in human cells, [75,76]. Nevertheless,
higher virus titres and multiple doses are needed to produce immune response equal to those induced
by the original smallpox vaccines [77–79]. LC16m8 is less attenuated than MVA and retains the ability
to replicate and cause lesions in human vaccinees, although the lesions were smaller than caused by the
parental Lister strain [69]. LC16m8 does not express the B5 protein, due to a frameshift mutation [80]
and this causes a small plaque phenotype. Notably humans immunised with LC16m8 show poor
immune responses to this protein [81], which is an important target for neutralising antibody against
the extracellular enveloped form of VACV [82]. Notably, both MVA and LC16m8 have not been shown
to prevent smallpox because they were used after smallpox was no longer endemic in the human
populations in which they were tested.
A fourth generation of smallpox vaccines are ones engineered to enhance safety and immunogenicity.
Strategies have included deleting genes encoding enzymes affecting nucleotide metabolism, proteins
that suppress the immune response to infection, or host range factors [13]. For example, strain New
York VACV (NYVAC) was derived from the Copenhagen strain after the deletion of 18 ORFs. Twelve
of these lie in a segment between the host range genes C7L and K1L. Two others (B13R and B14R)
are non-functional gene fragments that are an intact ORF in other VACV strains and encode a serine
protease inhibitor. Genes J2R and I4L encode thymidine kinase and the large subunit of ribonucleotide
reductase, respectively. Lastly, genes A26L and A56R encode structural proteins from intracellular
mature virions and extracellular enveloped virions, respectively [83]. Like MVA, NYVAC is unable to
replicate productively in human cells but unlike MVA, expression of some NYVAC late proteins is
inhibited due to a translational block [84]. Although attenuated, NYVAC still induces a potent immune
response [85,86].
In the last two decades, our knowledge of VACV immune evasion strategies has increased
immensely [87], thereby providing many target genes to engineer to obtain safer and more
immunogenic vaccines that elicit a protective immunological memory against orthopoxviruses.
The remaining part of this article is devoted to a consideration of these genes and the consequences of
deleting them on virus virulence and immunogenicity.
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4. Immune Response against Virus Infection: Basis for an Efficient Vaccine
Multicellular organisms have sophisticated mechanisms to fight viral infections. Upon sensing of
pathogen-associated molecular patterns (PAMPs), pathogen recognition receptors (PRR) are triggered
to activate intracellular signalling cascades. PRRs can be located either at the plasma membrane or
in endosomes, the cytosol or nucleus. They bind to different PAMPs, such as dsRNA by endosomal
Toll-like receptor 3 (TLR3) or cytoplasmic retinoic acid-inducible gene I (RIG-I), or cytoplasmic DNA
by DNA-dependent protein kinase (DNA-PK), reviewed by [88,89]. Then, PRRs activate signalling
pathways that lead to the activation of transcription factors that translocate to the nucleus to promote
gene expression. The transcription factors nuclear factor kappa light-chain enhancer of activated B
cells (NF-κB), interferon (IFN) regulatory factor 3 (IRF3) and activator protein (AP)-1 are key to this
first line of the innate immune response and stimulate the synthesis of IFNs, cytokines and chemokines
in response to sensing infection [90].
After release from producing cells, cytokines, chemokines and IFNs engage their cognate receptors
on the cell surface, inducing inflammation that amplifies the immune response and attracts other
immune cells to site of infection, reviewed by [91,92]. IFNs are key for the antiviral response through
the induction of IFN-stimulated genes (ISGs), which restrict virus infection at multiple levels, reviewed
by [93]. The outcome of these processes is to restrain virus replication and/or dissemination and
promote the elimination of the infection until immunological memory is developed, reviewed by [94].
This adaptive, or acquired, immune response is antigen-specific, unlike innate immunity that is
not specific to individual antigens. Antigen-presenting cells, such as macrophages, dendritic cells
(DCs) and B-lymphocytes display virus antigens complexed with class II major histocompatibility
complexes (MHCs) on their surfaces to T-lymphocytes [94]. Antibodies mediate neutralisation of virus
particles and CD8+ cytotoxic T-lymphocytes (CTL) cause lysis of infected cells [94]. Despite its delayed
onset, adaptive immunity provides a more rapid response upon repeated encounter with the same
virus [94]. Two other important components of the immune system are complement and natural killer
(NK) cells. Complement enhances the clearance of virions and virus-infected cells by antibodies and
phagocytic cells, reviewed by [95] and NK cells eliminate virus-infected cells before the development
of a virus-specific antibody and cytotoxic T-lymphocyte (CTL) response, reviewed by [96].
Immune Response against Vaccinia Virus Infection
The immune response against VACV infection has been studied after smallpox vaccination in
humans and infection in animal models, mainly in the mouse, reviewed by [97]. Of particular interest
are the studies that used intradermal or intranasal routes for virus infection because the former
resembles vaccination [98] whilst the later mimics natural infections with orthopoxviruses, such as
VARV and MPXV [97].
In the mouse intranasal model, VACV infects and replicates in the lung leading to inflammation
and tissue damage [99,100]. The virus disseminates to secondary sites, including lymph nodes, brain,
liver, kidneys, spleen, gastrointestinal tract and gonads. VACV replication in these organs results in a
second wave of viraemia that mimics the progression of some other orthopoxviruses in their hosts,
such as ectromelia virus (ECTV) in mice [101] and VARV in humans [11]. Expression of type I IFNs,
chemokines and cytokines, such as tumour necrosis factor (TNF)-α and IFN-γ, are upregulated in the
lungs and inflammatory cells are recruited, such as macrophages, T-lymphocytes and NK cells [98,102].
Early after infection, innate immune cells, such as macrophages, DCs and NK cells, restrict viral
replication in the lungs [102–104]. However, to limit VACV dissemination to secondary sites and
clear the infection, a VACV-specific CD8+ T-cell response is required [105–107]. IFN-γ is produced by
both NK cells and CD8+ T-cells and plays an important role in the resolution of respiratory VACV
infection [102,105].
In the intradermal mouse model, VACV replication remains local with little or no spread from the
primary site of infection and no signs of systemic disease [108]. After infection of skin, the inflammatory
infiltrate recruited to the site of infection is composed mainly of macrophages, neutrophils and
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T-cells [98,109]. Initially, macrophages control virus replication and tissue damage locally [110]. Later
during the adaptive phase, T-cells control the infection at the inoculation site and provide help for
B-cells to produce antibodies, which, in conjunction with T-cells, prevent viral dissemination and
promote virus clearance [111].
Studies with animal models have aided understanding of the components of the adaptive immune
system that provide protection against secondary orthopoxvirus infection and, therefore, should be
induced by vaccination. Whilst during primary infection, T-cells are sufficient for virus clearance before
antibodies can be detected, in mice immunised with replication-competent or replication-deficient
VACV strains, an antibody response can protect against both disease and mortality, with CD8+ T-cells
playing a role only in the absence of antibody [112–114]. NK cells can also mediate protection against
challenge in VACV-vaccinated mice in the absence of an adaptive T-cell response, demonstrating that
these cells too can have pathogen-specific memory [115]. Investigation of the immune response elicited
after smallpox vaccination and after natural orthopoxvirus infection in humans, also provides valuable
information that is useful for the design of more effective VACV-based vaccines [82,116–118].
5. Vaccine Engineering by Targeting Vaccinia Virus Proteins That Inhibit the Immune Response
To enter their host, replicate and be transmitted to new hosts, mammalian viruses must overcome
the hostile environment presented by the innate and adaptive immune system. Consequently, during
co-evolution with their hosts, viruses have acquired numerous countermeasures to evade or suppress
the immune response. Orthopoxviruses exemplify this well and encode scores of proteins devoted to
evasion of innate immunity. VACV is the most intensively studied orthopoxvirus and between one
third and one half of its approximately 200 genes are non-essential for replication but encode proteins
that affect host range, virulence or immune evasion [12,87].
From here on, the virulence, immunogenicity and protective efficacy of VACV strains engineered
to lack the expression of specific immunomodulatory or host range proteins is considered. Because
VACV encodes dozens of proteins that affect the outcome of infection in vivo, we focus primarily
on studies that tested the protective efficacy of VACV mutants lacking specific immunomodulators
against an orthopoxvirus challenge in the appropriate animal model. Engineered VACV strains are
also being tested as vaccine candidates against other infectious diseases, such as AIDS, tuberculosis
and malaria [65]. Most of the studies described here used VACV strain Western Reserve (WR), which
is not a human vaccine strain and was derived from the NYCBH vaccine strain by passage in the brain
of new-born mice [119]. Other studies investigated the effects of deleting immunomodulatory genes
from human vaccine strains such as MVA, Copenhagen, Lister, NYCBH and NYVAC.
5.1. Host Range Proteins
VACV exhibits a broad host range both in cell culture and in vivo, infecting many mammalian
species, such as rodents, lagomorphs, ungulates, non-human primates and humans [45,97,120].
The restricted host range of VACV strains lacking specific genes, such as genes K1L, C7L and E3L,
identified VACV host range proteins and the properties of these, and host range proteins from other
poxviruses, were reviewed [121]. Replication of VACV mutants engineered to lack E3L (v∆E3) or C7L
and K1L (v∆C7∆K1) is abortive in most mammalian cell lines [122,123]. The C7, E3 or K1 proteins
antagonise host antiviral factors, such as the ISG products, or prevent programmed cell death before
the virus has completed its replication cycle [124–127]. Mutants lacking these genes are attenuated
and their potential as vaccines has been investigated (Table 1).
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Table 1. VACV strains lacking host range proteins that have been tested for virulence and/or immunogenicity.
Protein Function
Virulence (Mouse) Virulence (Other Models) Protective Efficacy/Immune Response References
i.d. i.n. i.c. Rabbit (i.d.) Macaque (i.d.)
E3 dsRNA-binding protein ↓ ↓ ↓ ↓ ↓ ↓ protection (WR, NYCBH, MVA)n.c. CD8
+
T-cell response [128–133]
K1 NF-κB, PKR, IRF1 and type I IFN antagonist ↓ ↓ ↑ protection (WR)n.c. CD8+ T-cell response [134]
C7 PKR, IRF1 and type I IFN antagonist n.c. n.c. [135]
Virulence: virulence of mutant virus lacking the protein compared to controls in the indicated model. Protective efficacy: strain of VACV used for immunisation shown in brackets. Arrows
pointing up or down indicate increase or decrease, respectively, in virulence or protective efficacy. i.d. intradermal; i.n. intranasal; i.c. intracranial; n.c. no change. PKR, protein kinase R;
IRF1, interferon regulatory factor 1; NF-κB, nuclear factor kappa light-chain enhancer of activated B cells.
Viruses 2018, 10, 101 9 of 33
Despite lacking amino acid sequence similarity with each other, either C7 or K1 can restore
replication of v∆C7∆K1 in most mammalian cell lines by antagonising the effects of type I IFN [125]
and the antiviral effects of ISG products interferon regulatory factor (IRF)1 and SAMD9 [136,137].
K1 somehow blocks the activation of protein kinase R (PKR) by viral dsRNA, which leads to
activation of NF-κB and inhibition of host protein synthesis, even in presence of C7 [138,139]. K1 also
antagonises the activation of NF-κB by preventing the degradation of the inhibitor of κBα (IκBα) and,
further downstream in the pathway, by inhibiting the acetylation of p65 that is required for NF-κB
activation [140,141]. VACV strain MVA lacks the K1L gene but still encodes C7, which is essential for
late viral gene expression in human and murine cells [124].
A VACV WR mutant lacking K1 (v∆K1) replicated normally in cell culture but was attenuated in
both intradermal and intranasal mouse models of infection [134]. Infection via the intranasal route
induced less weight loss and lower virus titres compared to control viruses in primary (lungs) and
secondary (spleen, brain) organs [134]. Despite producing smaller dermal lesions, v∆K1 replicated as
well as wild-type and revertant controls and led to decreased immune cell infiltration and inflammatory
gene expression. Nonetheless, compared to control viruses, intradermal infection with v∆K1 elicited
the same levels of VACV-specific CD8+ T-cells and conferred the same protection against challenge
with VACV WR [134]. The comparable immunological memory induced by v∆K1, despite the muted
local inflammatory response, offers an opportunity to study the importance of the inflammatory
response elicited by an attenuated vaccine for its protective efficacy [142–144].
Genes C7L and K1L are amongst the 18 ORFs deleted from VACV strain Copenhagen to form
strain NYVAC [83], which does not replicate in human cells due to translational block and induction of
apoptosis [84]. Re-introduction of C7 in NYVAC restored growth in human cells but the virus virulence
remained unaltered [84]. Although the protective efficacy of NYVAC-C7 against an orthopoxvirus
challenge has not been tested, it has shown promise as a candidate vaccine against other diseases.
Re-insertion of gene C7L into NYVAC expressing four clade B HIV-1 antigens (env, gag, pol and
nef) (NYVAC-B-C7) elicited a stronger T-cell response to the HIV-1 antigens than did NYVAC-B in
a DNA prime/virus boost regimen in mice [126]. Also, NYVAC-C7 expressing Leishmania activated
C-kinase (LACK) elicited a stronger LACK-specific T-cell responses and was more protective than the
parental control vector against a Leishmania infantum intradermal challenge in a DNA prime/virus
boost regimen tested in mice [145].
Deletion of both C7L and K1L from VACV strain Tian Tan (VTT∆C7∆K1) induced greater
attenuation than single-deletion mutants (VTT∆C7 and VTT∆K1) in mice (intracranial and intranasal)
and rabbits (intradermal) [135]. Intramuscular vaccination of mice with VTT∆C7∆K1, induced a
lower antibody response whilst the T-cell response remained unchanged [135]. Future research
might study how the virulence and immunogenicity of C7L and K1L single- and double-deletion
mutants compare with other VACV strains and how well these mutants confer protection against an
orthopoxvirus challenge.
Deletion of gene E3L led to abortive replication in most mammalian cell lines [122]. E3 is a
multifunctional protein with an N-terminal Z-DNA-binding domain and a C-terminal RNA-binding
domain, both of which are required for virulence [146–148]. The C-terminal domain binds dsRNA and
prevents the activation of PKR and 2′5′-oligoadenylate synthase (OAS) [146–151]. E3 also counteracts
the antiviral activities of another ISG, ISG15 [152]. Through its RNA-binding domain, E3 also blocks
the sensing of RNA derived from the transcription of AT-rich DNA by RNA polymerase III [153,154].
The Z-DNA-binding domain prevents virus-induced necroptosis triggered via DNA-dependent
activator of IFN-regulatory factors (DAI) in IFN-treated cells [155]. Engagement of PKR by dsRNA
leads to activation of MAPK, NF-κB and IRF3, hence inhibition of PKR by E3 also interferes with the
stimulation of these three immune signalling pathways [156–158]. However, E3 inhibits NF-κB and
IRF3 activation independently of PKR [158,159]. In MVA, expression of E3 allows production of viral
intermediate and late proteins in human and murine cells [160].
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A VACV WR strain lacking E3 expression (v∆E3) is highly attenuated in vivo in normal and
immunodeficient mice infected via intranasal route or tail scarification; v∆E3 is also attenuated
when inoculated intracranially in immunocompetent mice [128,129]. Unlike WT virus, replication
of v∆E3 was limited to primary sites of infection (noses in the intranasal model, or skin in the
tail scarification model) and no dissemination to secondary sites was detected [128,129]. Gene E3L
deletion from NYCBH (NYCBH∆E3) and Copenhagen (vCop∆E3) caused attenuation in the murine
intranasal model [129] but immunisation via intranasal route or tail scarification protected mice against
VACV challenge [128,129]. Tail scarification induced a strong VACV-specific T-cell response and
immunological protection even in B-cell-deficient mice, highlighting that antibodies are not essential
for protection against VACV infection in mice [128].
NYCBH∆E3 vaccination by scarification was protective in alternative models as well, i.e., rabbitpox
virus (RPXV) infection in rabbits, ECTV in mice and MPXV in cynomolgus macaques. Whilst in mice,
vaccination with one or two doses of NYCBH∆E3 protected against a ECTV challenge, in rabbits,
two doses of NYCBH∆E3 were necessary to protect against high-dose RPXV challenge in comparison
to a single dose of NYCBH [130,131]. In rabbits, vaccination with NYCBH∆E3 did not prevent
development of secondary lesions in RPXV-challenged animals, though two doses of NYCBH∆E3
were as protective as one dose of NYCBH and both strains induced comparable titres of anti-VACV
neutralising antibodies [130]. In cynomolgus macaques, vaccination with two doses of NYCBH∆E3
conferred 75% protection against a MPXV challenge compared to 100% protection conferred by a
single dose of NYCBH [132]. Moreover, as observed in RPXV-challenged rabbits, NYCBH∆E3 did
not prevent viremia and development of secondary lesions in MPXV-challenged animals, whereas
NYCBH did [132]. Similar results were observed when E3L was deleted from MVA. Despite producing
comparable VACV-specific CD8+ T-cell responses, mice immunised with the resulting virus (MVA∆E3)
were less protected against a lethal ECTV challenge than mice immunised with MVA [133]. Altogether,
these results suggest that attenuation of vaccine strains by deletion of E3L might fail to produce a
sufficiently immunogenic and protective vaccine, probably because of the severe replication defects
exhibited by such deletion mutants.
5.2. Secreted Proteins
Some of the VACV immunoevasins are secreted from the infected cell and bind and inhibit
cytokines, chemokines, IFNs and complement factors extracellularly (Table 2).
Table 2. VACV strains lacking secreted immunomodulators that have been tested for virulence and/or
immunogenicity.
Protein Function
Virulence Protective Efficacy/Immune Response References
i.d. i.n. i.c.
A41 CC-chemokine binding protein ↑ ↑ ↑ protection (MVA)↑ CD8+ T-cell response [161,162]
B15 IL-1β binding protein n.c. ↑ ↓ ↑ protection (MVA)↑ CD8+ T-cell response [99,163–166]
C12 IL-18 binding protein ↓ (rabbit skin) ↓ ↓ ↑ protection (MVA) [98,167–169]
vCCI * CC-chemokine binding protein ↓ [170]
B8 IFN-γ binding protein ↓ (rabbit skin) n.c./↓ n.c. [171,172]
B18 type I IFN binding protein ↓ [173]
C21, VCP complement control protein ↓ ↑ protection (WR) [174,175]
Virulence: virulence of mutant virus lacking the protein compared to controls in indicated mouse model unless
stated otherwise. Immune response: changes in immunological memory. Protective efficacy: strain of VACV used
for immunisation shown in brackets. * Impact on virulence was done with a VACV WR strain engineered to express
Lister vCCI from the B8R gene locus (v∆B8-ListervCCI). Arrows pointing up or down indicate increase or decrease,
respectively, in virulence, protective efficacy or immune response. i.d. intradermal; i.n. intranasal; i.c. intracranial;
n.c. no change.
Viruses 2018, 10, 101 11 of 33
5.2.1. Protein C21: Vaccinia Complement Control Protein—VCP
VACV complement control protein (VCP, gene C21L) is related to complement control
proteins [176] and binds to C3b and C4b to block complement activation by either the classical or
alternative pathway [174,177,178]. VCP is not needed for replication in cell culture [177] but a deletion
mutant, v∆VCP, was attenuated in rabbits [174] and mice [175]. v∆VCP infection was associated with
increased infiltration of CD4+ and CD8+ T-cells, reduced local virus titres and increased VACV-specific
antibodies and all these differences were reversed to wild-type levels in complement-deficient C3−/−
mice [175]. Also, only concomitant depletion of CD4+ and CD8+ T-cells reversed lesion size and viral
titres in v∆VCP-infected mice, showing that protection against VACV infection in the intradermal
mouse model is mediated both by CD4+ T-cell- (i.e., antibody-dependent) and CD8+ T-cell-dependent
mechanisms [175]. Intradermal infection with v∆VCP induced better protection than wild-type against
VACV challenge [175].
5.2.2. Protein A41: A Secreted Chemokine-Binding Protein
A41 is another secreted protein encoded by VACV [161]. A41 binds CC chemokines CCL21, CCL25,
CCL26 and CCL28 and prevents their interaction with glycosaminoglycans and the formation of a
chemokine concentration gradient that is important for the recruitment of leukocytes [179]. A VACV
WR lacking gene A41L (v∆A41) replicated normally in cell culture but had slightly increased virulence
in the murine intranasal model and produced larger lesions after intradermal infection of mouse ear
pinnae and increased infiltration into infected rabbit skin [161,162]. Despite increased lesion size,
v∆A41-infected mice cleared the infection more rapidly than controls [161]. In the murine intranasal
model, no difference in the viral titres and in the pulmonary CD8+ T-cell response was observed with
v∆A41. Nevertheless, v∆A41 caused an increase in the VACV-specific splenic CD8+ T-cell response
compared to mice infected with control viruses [162]. The VACV-specific CD8+ T-cell response also
increased in the spleens of mice immunised by a prime-boost regimen with an MVA strain lacking A41
(MVA∆A41). More importantly, MVA∆A41 immunisation conferred better protection against VACV
challenge, suggesting it is a more potent vaccine [162].
5.2.3. vCCI: A Secreted CC Chemokine-Binding Protein
VACV protein A41 is related to another CC-chemokine-binding protein expressed by some
VACV strains (e.g., Lister and RPXV) but not by others (e.g., Copenhagen and WR). This protein is
called VACV chemokine-binding protein (vCKBP) or VACV CC chemokine inhibitor (vCCI) [180–183].
Soluble vCCI binds with high affinity to CC (RANTES, MIP-1α, MCP-1, eotaxin) but not CXC (IL-8,
GROα, ENA-78) or C (lymphotoxin) chemokines, thereby blocking their interaction with cellular
receptors [180]. The impact of vCCI expression on VACV virulence was investigated with a VACV WR
strain engineered to express Lister vCCI from the B8R gene locus (v∆B8-ListervCCI) [170]. The absence
of protein B8 did not affect virulence in murine models of infection [163,171]. v∆B8-ListervCCI induced
reduced weight loss, signs of disease and mortality after intranasal infection in comparison to v∆B8,
indicating that vCCI expression attenuated VACV virulence [170]. Attenuation due to vCCI expression
was associated with lower viral titres and viremia, reduced pulmonary recruitment of leukocytes
(mainly macrophages and lymphocytes) and consequently decreased inflammation and oedema [170].
The impact of vCCI on immunogenicity needs to be investigated.
5.2.4. C12: A Soluble IL-18-Binding Protein
VACV encodes several secreted, cytokine-binding proteins. One example is C12, an early,
non-essential protein [167]. C12 binds interleukin (IL)-18 [167,184,185] and blocks IL-12-induced
production of IFN-γ [167], which acts in synergy with IL-12 to regulate the immune response. A virus
lacking the C12L gene (v∆C12) was attenuated after intranasal infection of mice [167] and there was
increased IL-18 and enhanced NK-cell cytotoxicity early at 3 days post-infection (dpi) in the lungs.
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Later, at 7 dpi, IL-18 led to increased production of IFN-γ and nitrite and enhanced CTL response
in the lungs of v∆C12-infected mice. C12 therefore counteracted the effects of IL-18 in both innate
and adaptive immune responses against VACV infection [186]. Deletion of C12L also attenuated VTT,
which formed smaller lesions in rabbits infected intradermally and had a lower LD50 in the intracranial
model of infection in mice [168]. An MVA strain lacking C12 expression (MVA∆C12) elicited a stronger
immune response than wild-type control in mice, independently of the immunisation route [169].
Furthermore, mice immunised intraperitoneally with MVA∆C12 lost less weight and had reduced
signs of illness then MVA-immunised mice after challenge with VACV WR [169]. This protection
correlated with a stronger VACV-specific CD8+ T-cell response. Loss of C12 also enhanced the immune
response to HIV antigens expressed by MVA∆C12 [169].
5.2.5. Protein B15: A Soluble IL-1β Receptor
VACV WR protein B15 (IL-1β receptor) binds and inhibits human and mouse IL-1β but not
IL-1α or the IL-1 receptor antagonist protein [99]. B15 is expressed by several VACV strains but not
Copenhagen and is non-essential for VACV WR replication [99]. VACV WR v∆B15 was more virulent
in mice infected intranasally at high doses [99]. In contrast, lack of B15 resulted in reduced virulence
after intracranial infection of mice [164]. Intranasal infection with v∆B15 induced a febrile response,
unlike control viruses, indicating that IL-1β is controlling the induction of fever [187]. Deletion
of the MVA counterpart of B15 did not affected MVA replication in CEFs but the deletion mutant
MVA∆184 induced better protection against intranasal challenge with VACV WR, even six months
after vaccination, due to enhanced CD8+ T-cell memory [165]. Another study with MVA also reported
enhanced CD8+ T-cell responses followed knock out of this gene [166].
5.2.6. Proteins B8 and B18: IFN-Binding Proteins
VACV strain WR proteins B8 and B18 encode secreted proteins that bind IFN-γ or type I IFNs,
respectively. Protein B8 has similarity to the mouse and human IFN-γ receptor (IFN-γR) and to protein
M-T7 from myxoma virus [188] and acts as a soluble antagonist of IFN-γ [189,190]. Unlike cellular
IFN-γRs that bind IFN-γmostly from the same species, B8 bound human, bovine, rat and rabbit IFN-γ
with high affinity and to mouse IFN-γ with low affinity [189,190]. B8 functions as a homodimer [191]
and also binds equine IFN-γ [171]. A VACV WR strain lacking gene B8R had normal virulence in mice
but was attenuated in rabbit skin [171,192]. Another study found reduced virulence in mice without
reduction in humoral immunity [172].
VACV WR protein B18 is an extracellular inhibitor of type I IFNs [173,193] and a member of the
immunoglobulin superfamily [194]. Like B8, B18 inhibits IFNs from many species (human, rabbit,
bovine, rat and mouse) and is a virulence factor in mouse models of infection [173]. B18 binds to
glycosaminoglycans on the surface of cells [195] and so inhibits type I IFNs on the cell surface and in
solution [196]. Deletion of B8R, B18R or both genes, from a NYVAC strain engineered to expresses
HIV-1 clade C Env, Gag, Pol and Nef antigens (NYVAC-C) improved HIV-1-specific CD8+ T-cell
responses [197].
5.2.7. Other VACV Secreted Proteins
Several other VACV proteins are secreted from infected cells but are not considered further
here because their influence on the immune response to infection and protection from challenge has
not been studied in detail. These include A53, a secreted TNF-α receptor made by VACV strains
Lister, USSR, Evans and Tian Tan, also called cytokine response modifier (crm)E [168,198,199]; protein
C11, the VACV epidermal growth factor (VGF) responsible for the dermal hyperplasia characteristic
of orthopoxvirus infections [200,201]; and protein A39 a secreted glycoprotein with similarity to
semaphorins that influences virus virulence and the immune response to infection [202,203].
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5.3. Intracellular Immunomodulators
The majority of the VACV immunomodulatory proteins act intracellularly to block innate immune
signalling pathways that culminate in the production of IFNs, cytokines and chemokines, or the
induction of programmed cell death. For instance, VACV encodes at least ten proteins that inhibit
NF-κB activation intracellularly (A46, A49, A52, B14, C4, E3, K1, K7, M2 and N1) and six that inhibit
IRF3 activation (A46, C6, C16, E3, K7 and N2), for review see [87]. Several of these proteins have
multiple functions. These proteins are considered in 2 groups: those with similarity to Bcl-2 (Table 3)
and those lacking such similarity (Table 4).
Table 3. VACV strains lacking intracellular Bcl-2-like immunomodulators that have been tested for
virulence and/or immunogenicity.
Protein Function
Virulence Protective Efficacy/Immune Response References
i.d. i.n. i.c.
B14 NF-κB inhibitor ↓ n.c. [204]
N1 NF-κB and apoptosis inhibitor ↓ ↓ ↓ ↑ protection (WR)↑ CD8+ T-cell response [205–208]
K7 NF-κB and IRF3 inhibitor ↓ ↓ ↑ protection (WR) [209]
A52 NF-κB inhibitor ↓ [210]
A46 NF-κB, IRF3 and MAPK inhibitor ↓ [211]
C6 IRF3 and JAK/STAT inhibitor ↓ ↓ ↑ protection (WR)↑ CD8+ T-cell response [212,213]
N2 IRF3 inhibitor ↓ ↓ n.c. protection (WR) [214]
F1 apoptosis and inflammasome inhibitor ↓ ↓ protection (MVA)n.c. CD8+ T-cell response [133,215]
Virulence: virulence of mutant virus lacking the protein compared to controls in indicated mouse model. Immune
response: changes in immunological memory. Protective efficacy: strain of VACV used for immunisation shown in
brackets. Arrows pointing up or down indicate increase or decrease, respectively, in virulence, protective efficacy or
immune response. i.d. intradermal; i.n. intranasal; i.c. intracranial; n.c. no change.
Table 4. VACV strains lacking other intracellular immunomodulators that have been tested for
virulence and/or immunogenicity.
Protein Function
Virulence Protective Efficacy/Immune Response References
i.d. i.n. i.c. i.p.
C4 NF-κB inhibitor n.c. ↓ [216]
C16 inhibitor of DNA sensing andpromoter of hypoxic response n.c. ↓ n.c. protection (WR) [217]
D9 de-capping enzyme n.c. n.c. n.c. protection (WR) [218]
D10 de-capping enzyme ↓ ↓ n.c. protection (WR) [218]
169 inhibitor of translation ↑ ↑ ↑ protection (WR)↑ CD8+ T-cell response [219]
A35 inhibitor of MHC class IIantigen presentation ↓ ↓ ↑ protection (WR)n.c. protection (MVA) [220–222]
A44 3β-hydroxysteroid dehydrogenase ↓ ↓ ↓ [163,223,224]
Virulence: virulence of mutant virus lacking the protein compared to controls in indicated mouse model. Immune
response: changes in immunological memory. Protective efficacy: strain of VACV used for immunisation shown in
brackets. Arrows pointing up or down indicate increase or decrease, respectively, in virulence, protective efficacy or
immune response. i.d. intradermal; i.n. intranasal; i.c. intracranial; i.p. intraperitoneal; n.c. no change.
5.3.1. VACV Bcl-2-Like Proteins
VACV encodes a family of proteins with similarity to B-cell lymphoma (Bcl)-2 [225]. Some of these
proteins were noted to share limited (~20%) amino acid (aa) identity [226,227] but their relatedness to
Bcl-2 proteins was only revealed after the structures were solved by X-ray crystallography, such as N1,
B14, A52 and F1 [228–231]. Other VACV proteins shown to have a Bcl-2 fold are A46 [232], A49 [233]
and K7 [234,235], and proteins C6 [212,236] and N2 [214] are predicted to adopt a Bcl-2 fold. A function
for most of these proteins has been reported and several of these proteins have multiple functions.
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Protein B14: An NF-κB Inhibitor
B14 is a cytosolic, early protein that is non-essential for replication but contributes to virulence
and affects the recruitment of leukocytes [204]. B14 inhibits NF-κB activation at the level of the IκBα
kinase (IKK) complex by binding to IKKβ and preventing its phosphorylation by upstream kinases and
consequently preventing the phosphorylation of IκBα [237]. MVA protein 183 shares 95% aa identity
with VACV WR B14 but is unstable due to mutation and does not inhibit NF-κB activation [238].
Using the B14 structure [230], a F130K mutation was found to no longer bind IKKβ or inhibit NF-κB
activation [239].
Protein N1: An Inhibitor of Apoptosis and NF-κB
Like B14, N1 is an early, non-essential protein that promotes virulence [205,206]. N1 inhibits NF-κB
activation, although the exact mechanism is uncertain [207,229,240]. N1 forms a homodimer [206] and
its structure [228,229] revealed a Bcl-2 fold with a surface groove through which it binds BH3 peptides
from pro-apoptotic Bcl-2 proteins [228,229] and thereby inhibits apoptosis [207]. Mutations that fill the
surface groove ablated the ability to inhibit apoptosis, whereas mutation of the hydrophobic dimer
interface disrupted dimerization and prevented inhibition of NF-κB [207]. Separation of these functions
showed that the ability to inhibit NF-κB activation was important for virulence whereas inhibition of
apoptosis was not [207]. The attenuation of a mutant VACV WR lacking the N1L gene (v∆N1) was
linked to a stronger pulmonary NK-cell and CD8+ T-cell response during acute infection [109,241].
Immunisation of mice with v∆N1 or a virus expressing vN1-I6E (an N1 mutant unable to dimerise and
inhibit NF-κB activation) induced increased protection against intranasal challenge with VACV WR
due to stronger CD8+ T-cell memory [208,241].
Protein K7: An NF-κB and IRF3 Inhibitor
Protein K7 is another early, non-essential VACV protein that promotes virulence [209]. K7 binds
to IL-1 receptor-associated kinase 2 (IRAK2) and TNF receptor-associated factor 6 (TRAF6) to inhibit
the NF-κB pathway [235,242]. Additionally, K7 prevents IRF3 activation by interacting with the
DEAD-box RNA helicase 3 (DDX3) protein [242]. The structure of K7 revealed a Bcl-2 fold but it
lacked a surface groove for binding of BH3 peptides [234,235]. Loss of K7 caused virus attenuation
in both dermal and intranasal murine models of infection and analysis of infected lungs showed
increased infiltrating T-cells and activated macrophages, as well as higher pulmonary NK cell- and
CTL-dependent cytotoxic responses [209]. Immunisation with VACV WR lacking K7 induced better
protection against challenge [243]. Similarly removal of the K7L gene together with gene C6L from
VACV strain MVA induced stronger CD8+ T cell responses against HIV antigens expressed by this
virus [244], although in this study the cause of this change was not analysed by deletion of these
genes separately.
Protein A52: An NF-κB Inhibitor
VACV WR protein A52 is another inhibitor of NF-κB activation and, like K7, can bind to IRAK2
and TRAF6 [210,245]. A52 is expressed early, is non-essential for virus replication and promotes
virulence in the murine intranasal model [210]. The structure of A52 showed it is a Bcl-2 protein [230].
The NYVAC strain encodes A52, B14 and K7 and derivative strains engineered to lack one, two
or all three genes were tested as candidate HIV vaccines. This showed that, to different extents,
these NYVAC deletion-mutants increased cell infiltration, cytokine and chemokine production and
HIV-specific CD8+ T-cell and antibody responses after intraperitoneal infection of mice [246]. These
results highlight the potential of these proteins as targets for further vaccine engineering.
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Protein A46: An Inhibitor of IRF3, NF-κB and MAPK Pathways
A46 is another NF-κB antagonist with a Bcl-2 fold [232]. A46 is expressed early during infection
and binds to adaptor molecules downstream of Toll-like receptors (TLRs) and therefore inhibits the
activation of downstream NF-κB, IRF3 and MAPK pathways [211,245,247,248]. A VACV WR A46R
deletion mutant is attenuated in the intranasal model of infection compared to control viruses and
caused an increased and accelerated pulmonary infiltrate [211]. The potential of v∆A46 as a vaccine is
yet to be investigated.
An interesting feature of A46 is an N-terminal region before the Bcl-2 fold and recently this
structure was solved and shown to have a novel β-sheet fold that contains a myristic acid binding
pocket [249].
Protein C6: And IRF3 and JAK-STAT Signalling Inhibitor
C6 is an early, non-essential protein that enhances virulence [212]. C6 inhibits activation of IRF3
and IRF7 by binding to the adaptor proteins needed to activate the upstream kinases TANK-binding
kinase 1 (TBK1) and IKKε. Consequently, C6 restricts the production of type I IFNs [212]. C6 also
inhibits activation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT)
signalling pathway following binding of type I IFN to the type I IFN receptor and so prevents
transcription of ISGs containing the IFN-stimulated response element (ISRE) [236]. C6 inhibits this
pathway in the nucleus, after IFN-stimulated gene factor 3 (ISGF3) binds to the ISRE element and
might mediate this inhibition by its association with STAT2 [236]. Vaccination with v∆C6 induced
enhanced CD8+ T-cell responses and better protection against VACV challenge [213]. Deletion of gene
C6L from MVA also increased the both humoral and CD4+ and CD8+ T-cell memory responses against
HIV-1 antigens expressed by MVA [250].
Since the deletion of genes N1L, C6L and K7R individually caused increased immunogenicity and
decreased virulence, another study investigated whether deleting these genes in combination would
improve immunogenicity further. In vivo the attenuation caused by deletion of each single gene was
increased stepwise by deletion of the second and third gene in both intranasal and intradermal mouse
models [243]. However, although intradermal vaccination with v∆N1 induced better protection against
challenge [208], deletion of N1L and K7R together, or all three genes resulted in inferior protection
that correlated with a decrease in CD8+ T-cell response and in neutralising antibody titre [243].
Further studies are needed to investigate if deletion of multiple genes in other VACV strains, such
as the MVA, gives a similar outcome. In some cases, the deletion of multiple immunomodulators
from MVA increased immunogenicity [244,251], however, in another study, an MVA strain lacking
fifteen immunomodulatory genes induced similar CD8+ T-cell response against both VACV-specific
or heterologous antigen peptides [252]. Collectively, these studies highlight that a balance between
attenuation and immunogenicity is important in the design of future vaccines.
Protein N2: An IRF3 Inhibitor
N2 is an early, nuclear, non-essential protein with a predicted Bcl-2 fold that inhibits IRF3
activation by an unknown mechanism [214]. N2 is highly conserved in VACV strains but in MVA it
lacks residues 31–35. VACV WR lacking N2 was less virulent and induced an increased pulmonary cell
infiltration but nonetheless induced similar protection to challenge compared to control [214]. However,
a MVA lacking N2 and expressing clade B HIV-1 antigens (MVA-B∆N2) elicited greater HIV-1-specific
CD4+ and CD8+ T-cell responses and greater HIV-specific antibodies, although anti-VACV-specific
antibodies remained unchanged [253].
Protein F1: An Inhibitor of Apoptosis and the Inflammasome
Protein F1 is expressed early and is a potent inhibitor of apoptosis [254,255]. F1 has a Bcl-2-like fold
with a surface groove for binding BH3 peptides [231]. F1 also binds and inhibits caspase 9 [256] and
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blocks inflammasome activation by binding the NOD-like receptors (NLR) family member NACHT,
LRR and PYD domains-containing protein 1 (NLRP1) [215]. Mutational analysis of F1 separated
inhibition of the inflammasome from inhibition of apoptosis and in vivo analysis showed that inhibition
of the inflammasome was important for virus virulence [215]. Deletion of F1L from MVA reduced its
protective capacity against a lethal ECTV challenge in mice, without affecting virus-specific CD8+ T-cell
responses [133]. Nevertheless, deletion of F1L from an MVA strain expressing Env and Gag-Pol-Nef
antigens from clade C HIV-1 (MVA-C-DeltaF1L) enhanced HIV-1-specific CD8+ T cell adaptive immune
responses following a prime-boost immunisation programme [257].
5.3.2. Proteins C4 and C16
VACV WR proteins C4 and C16 share 43% aa identity and are early, non-essential proteins that
promote virulence [216,217]. C16 inhibits DNA sensing leading to IRF3-dependent innate immunity
by binding to the Ku proteins Ku70 and Ku80 [258], which are subunits of the DNA-PK complex that
functions as a DNA sensor [259]. C16 binds the Ku proteins via its C-terminal domain, whereas the
N-terminal region binds the oxygen sensor prolylhydroxylase domain-containing protein 2 (PHD2).
The latter interaction prevents PHD2 hydroxylating hypoxia-inducible transcription factor (HIF)-1α
and the subsequent ubiquitylation and degradation of HIF-1α. Thus HIF-1α is stabilised, migrates
to the nucleus and induces transcription of genes bearing the HIF-responsive element leading to a
hypoxic response [260]. In turn, this leads to re-programming of central energy metabolism with a
switch from oxidative phosphorylation to glycolysis [261]. C16 is conserved in several VACV strains,
including WR, Copenhagen, Lister and MVA [217], although an internal 5-aa deletion in MVA C16
greatly reduces binding to Ku [258]. Mice infected intranasally with v∆C16 showed a faster pulmonary
recruitment and activation of CD4+ and CD8+ T-cells [217]. The effect of C16 on immunological
memory has not been reported.
Protein C4 inhibits NF-κB activation at or downstream of the IKK complex [216]. Like C16, C4
affected virulence in the intranasal but not intradermal, mouse model and its deletion caused increased
pulmonary infiltration of leucocytes [216]. A comparison of the conservation of C4 and C16 amongst
orthopoxviruses showed that few viruses expressed both proteins but all express either one or the
other, suggesting a conserved and important function [216,217]. It will be interesting to investigate
the in vivo phenotype of a VACV strain lacking both C16 and C4 and the effects on the induction of
immunological memory.
5.3.3. De-Capping Enzymes D9 and D10
VACV also blocks activation of host immune responses by targeting protein translation. D9 and
D10 are de-capping enzymes expressed either early (D9) or late (D10) during infection [262,263]. Both
enzymes remove the cap from cellular and viral mRNAs and are important for shutting off host
protein synthesis and for enhancing turnover of viral mRNAs and thereby the transition from the
early to intermediate to late phases of virus protein expression [262,263]. D9 and D10 also cooperate
to prevent the formation of dsRNA in infected cells, thereby blocking the activation of PKR [218].
The absence of a functional D10 enzyme but not D9, caused virus attenuation in mice in both intranasal
and intraperitoneal models of infection [218]. However, when both D9 and D10 had inactivating
mutations in their catalytic sites, the mutant VACV exhibited a replication defect in cell culture and
severe attenuation in vivo [218]. Although highly attenuated, this double-mutant virus protected mice
against challenge with VACV WR [218].
5.3.4. Protein 169: An Inhibitor of Translation
Protein 169 is an early, small, charged, intracellular non-essential protein that suppresses the
immune response by inhibition of cap-dependent and cap-independent translation initiation [219].
A VACV WR mutant lacking 169 expression (v∆169) is more virulent in infected mice, causing
larger lesions after intradermal infection or greater weight loss after intranasal infection [219]. Mice
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immunised with v∆169 were better protected against challenge with VACV than mice infected with
control viruses [219]. Early after infection with v∆169 there was increased pulmonary cell infiltration
and increased production of inflammatory cytokines and chemokines. Later there was increased
macrophage and T-cell (CD4+ and CD8+) infiltration in the lungs but no difference in neutralising
antibodies levels [219].
5.3.5. Protein A35
Protein A35 is an intracellular, hydrophobic protein that localises to virus factories and contributes
to virulence [220]. A35 restricts antigen presentation to T-cells via MHC class II. Infection with a
virus lacking A35 (v∆A35) induced lower VACV-specific antibodies and IFN-γ secretion and lysis
by splenocytes [221,264]. Despite being attenuated, v∆A35 conferred equivalent protection against
challenge [221]. Immunisation with MVA lacking A35R (MVA∆A35) also induced protection as well as
wild-type MVA [222]. MVA∆A35 induced greater VACV-specific antibodies, an increased percentage
of granulocytes, CD11b+ cells and IFN-γ-producing cells in spleen but no difference in the percentage
of CD8+ T-cells [222]. Deletion of A35R from an L-IPV strain lacking genes C3L, N1L, J2R, A56R and
B8R, induced greater VACV-neutralising antibody when used in prime-boost regimen and equivalent
protection against ECTV challenge [265].
5.3.6. Protein A44: A 3β-Hydroxysteroid Dehydrogenase
Protein A44 shares 31% aa identity with human 3β-hydroxysteroid dehydrogenase (3β-HSD),
an enzyme needed for steroid biosynthesis [226,227,266]. Several other poxviruses such as molluscum
contagiosum virus [267], fish lymphocystis virus [268] and avipoxviruses (fowlpox virus and canarypox
virus) [269] also encode 3β-HSD. VACV A44 is an active 3β-HSD and is an early, non-essential protein
that promotes virulence [163,223,224]. VACV WR lacking 3β-HSD caused reduced corticosterone in
lungs and plasma and an enhanced inflammatory response. There were increased IFN-γ levels, more
rapid recruitment of CD4+ and CD8+ T-cells and a stronger cytolytic T-cell response to VACV-infected
cells [270]. Immunisation of mice with VACV strain Praha or Dryvax derivatives lacking 3β-HSD
and expressing either varicella-zoster virus glycoprotein E or hepatitis B virus glycoprotein pre-S2
showed either no difference in antibody levels to VACV or the foreign antigens, or a slight reduction,
depending on the parental strain used [224].
5.3.7. Other Intracellular Virulence Factors or Immunomodulators
Many other VACV proteins, either immunomodulators or proteins with other functions, affect
virulence and/or the host immune response. These include I4 (ribonucleotide reductase large
subunit) [271,272], J2 (thymidine kinase) [273], A26 (virion attachment/entry) [274], B5 (virion
envelope glycoprotein related to complement control factor) [275,276], B13 and B22 (serine protease
inhibitors SPI-2 and SPI-1, respectively) [163,277–279], F12 (IEV transport protein) [280], A36 (IEV
transport protein and actin tail inducer) [163,281], A40 (cell surface glycoprotein) [163,282], A50 (DNA
ligase) [283], C2, F3 and A55 (intracellular kelch protein immunomodulators) [284–286] and A33
(virion envelope glycoprotein) [276], However, the protective capacity of viruses lacking these proteins
requires further study.
5.4. Expression of Cellular Immunomodulators from Vaccinia Virus
An alternative strategy to improve safety and/or immunogenicity of VACV vaccine is the
expression of cellular immunomodulators from the virus. This strategy has been tested with
recombinant VACV strains expressing cytokines such as IL-2 [287,288], IL-4 [289], IL-18 [290],
IFN-γ [291–293], IFN-λ2 and IFN-λ3 [294]. Whereas expression of IL-4 from VACV delayed virus
clearance in mice, VACV expressing IL-2, IL-18, IFN-γ or IFN-λ are attenuated in vivo. Also, expression
of chemokine CCL20 or colony-stimulating factor GM-CSF from MVA induces a stronger virus-specific
CD8+ T-cell and antibody responses after immunisation of mice [295].
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6. Conclusions
Safer and immunogenic vaccines against orthopoxviruses are needed to combat emerging
orthopoxvirus infections in Europe, South America and India, monkeypox in Africa and the possible
re-creation of orthopoxviruses by synthetic biology [20]. The VACV genome encodes scores of
immunomodulatory proteins, some of which remain poorly or incompletely characterised [87]. Many
VACV mutants engineered to lack these immunomodulatory proteins display an altered virulence
and/or immune responses, showing that engineering safer and more potent VACV vaccines is
possible [87]. Although the use of attenuated replication-deficient strains, like NYVAC and MVA,
is desirable for use in those with immunodeficiency [76], immunisation with NYVAC and MVA
requires higher or multiple doses to confer the same protection as replication-competent strains [112].
Deletion of some immunomodulatory genes, for examples A41L and A35R, has increased the
immunogenicity of MVA [162,222]. On the other hand, deleting the host range gene E3L produced
inferior vaccines, possibly due to restricted replication of the vaccine, illustrating that there is
balance between vaccine replication/attenuation and immunogenicity/protection [130,132]. Further
research is needed on proteins whose deletion increases protective efficacy but also the virulence
of replication-competent strains, like VACV WR protein 169 [219]. It would be interesting to study
the consequence of deleting 169 from replication-deficient strains that encode it, such as MVA, or to
restore its expression in strains that lack it, such as NYVAC. The optimal balance between attenuation,
immunogenicity and immunisation dose is hard to predict and needs to be evaluated on a case-by-case
basis. So far, the deletion of multiple immunomodulatory genes has not given predictable outcomes
for immunogenicity in animals [243,265] and how these will affect outcomes in humans is unknown.
A systematic analysis of different combination of deleted genes, along with comparison with wild-type,
single-deletion and revertant controls, is necessary to work out the role of individual genes and
whether this is a good strategy for engineering of VACV vaccines. Synthetic biology might be a useful
tool to rapidly construct different combinations of gene deletions from custom-synthesized VACV
genomes with desired modifications.
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